430
Efficacy of Pegylated Interferon α-2a Therapy
for HBsAg ≤1500 IU/Ml CHB Patients with a
Prior Nas History
Fengping Wu, Yaping Li, Mei Li, Wenjun Wang, Xiaoli Jia,
Xin Zhang, Juanjuan Shi and Shuangsuo Dang, The Second
Affiliated Hospital of Xi’an Jiaotong University
Background: HBsAg clearance with or without
seroconversion is a ideal goal of antiviral therapy for chronic
hepatitis B virus (CHB) patients. However, the clearance
rate is extremely low with nucleos(t)ide analogs (NAs) or
interferon monotherapy. We comprehensively evaluated
that the efficacy of pegylated interferon α-2a (Peg-IFNα-2a)
therapy for HBsAg ≤1500 IU/mL CHB patients with a prior
NAs history, which will provide a more optimized treatment
plan for CHB patients. Methods: 185 HBeAg-negtive CHB
patients under persistent virological suppression and HBsAg
≤1500 IU/mL after more than 1 year of NAs therapy were
enrolled, which were randomly divided into the trial group
(n=85) and the control group (n=100). Patients in trial group
received NAs combined with Peg-IFNα-2a treatment for 48
weeks and followed-up for 24 weeks. Patients in control group
received NAs monotherapy continuously. HBsAg clearance
and seroconversion rates at week 72 were used to evaluate
the therapeutic efficacy. Results: Per-protocol (PP) analysis
showed that HBsAg clearance and seroconversion rate in the
trial group were 28.2% and 20.0% at week 48, increased to
40.0% and 32.0% at week 72. However, the HBsAg clearance
rate in control group were 1.0% at week 48 and 2.0% at week
72, and no patient achieved seroconversion (Figure 1). In the
trial group, the proportions of patients who achieved HBsAg
≤1000 IU/mL, ≤ 100 IU/mL, ≤ 10 IU/mL at week 72 were
100.0%, 76.0%, 58.0%, respectively, while the proportions
were 25.0%, 17.0%, 9.0% in the control group, respectively.
Baseline HBsAg <500 IU/mL, HBsAg <200 IU/mL at 24
weeks treatment, ALT≥2 ULN at the early 12 weeks treatment
were independent predictors of HBsAg clearance. The
incidence of common adverse events (including headache,
alopecia, and pyrexia) were similar to previous studies and
all patients had good tolerance to these treatments in the trial
group. Conclusion: For HBeAg-negtive CHB patients under
persistent virological suppression and HBsAg ≤1500 IU/mL
after more than 1 year of NAs therapy, combining with Peg-
IFNα-2a therapy for 48 weeks is a more optimized treatment
plan for CHB patients作者: StephenW 时间: 2018-10-20 13:07
Results: Per-protocol (PP) analysis
showed that HBsAg clearance and seroconversion rate in the
trial group were 28.2% and 20.0% at week 48, increased to
40.0% and 32.0% at week 72. However, the HBsAg clearance
rate in control group were 1.0% at week 48 and 2.0% at week
72, and no patient achieved seroconversion (Figure 1).
说明效果不错啊！！信心很重要。